Qureator Demonstrates Translational Modeling of Pharmacology and Safety of PD-1xVEGF BsAb and T-Cell Engager Using vTIME 3D Platform at SITC 2026

SAN DIEGO--(BUSINESS WIRE)--Qureator, a leading techbio company delivering regulatory-grade translational data through its vTIME 3D human tissue platform, presented preclinical data evaluating the dual pharmacology of a PD-1xVEGF bispecific antibody and the vascular safety profile of a T-cell engager in a poster at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting. “Developing effective cancer therapies requires a deeper understanding of how treatments interact with the complex

The post Qureator Demonstrates Translational Modeling of Pharmacology and Safety of PD-1xVEGF BsAb and T-Cell Engager Using vTIME 3D Platform at SITC 2026 appeared first on BusinessWire.

For more information, please visit http://www.businesswire.com/news/home/20261109490773/en/Qureator-Demon…